Doxorubicin carrier based on an HCOF platform for potent cancer therapy
Dalton Transactions · 2025
DOI: 10.1039/d5dt00486a ↗Kurz gefasst
Fachartikel in der Zeitschrift Dalton Transactions, 2025. Verfasst von Tingyan Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541001, P. R. China. mlpang@gxnu.edu.cn. Hauptthemen laut MEDLINE: Doxorubicin, Drug Carriers, Metal-Organic Frameworks, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Specific Research Project of Guangxi for Research Bases and Talents, National Natural Science Foundation of China.
Abstract (Originalsprache)
Doxorubicin is widely used in cancer treatment, and an effective drug carrier is usually needed to overcome its serious side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541001, P. R. China. mlpang@gxnu.edu.cn.
ORCID-Profile: Xianhao Wei, Maolin Pang
Förderung
- Specific Research Project of Guangxi for Research Bases and Talents
- National Natural Science Foundation of China
Zitieren
APA
Jiang, T., Liu, M., Qiao, J., Wei, W., Wei, X., Zhang, L., Wang, Y., Ou, J., & Pang, M. (2025). Doxorubicin carrier based on an HCOF platform for potent cancer therapy. Dalton Transactions. https://doi.org/10.1039/d5dt00486a
Vancouver
Jiang T, Liu M, Qiao J, Wei W, Wei X, Zhang L, et al. Doxorubicin carrier based on an HCOF platform for potent cancer therapy. Dalton Transactions. 2025. doi:10.1039/d5dt00486a
BibTeX
@article{Jiang2025,
author = {Jiang, Tingyan and Liu, Meng and Qiao, Jiarui and Wei, Wenjing and Wei, Xianhao and Zhang, Luwen and Wang, Yan and Ou, Junhe and Pang, Maolin},
title = {Doxorubicin carrier based on an HCOF platform for potent cancer therapy},
journal = {Dalton Transactions},
year = {2025},
doi = {10.1039/d5dt00486a}
}
EUVIMED